You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration.
Francis Crick, one of the most famous scientists of our generation, described a double helix structure that is now known to characterize human DNA (this discovery was published in 1953 along with his colleague James Watson). Later, in the 1970s, Crick discussed a wish-list for future discoveries, including the use of light to control human cells. Light science and light therapy have since been considered both “crazy and far-fetched”; however, recent discoveries in the early 21st century have dramatically changed this point of view. Thanks to some very clever scientists, a new field called optogenetics was born.
What is optogenetics? The “opto-“ refers to placing light onto the brain to activate channels and/or enzymes that will ultimately change brain cell firing. The technique is specific, and has the potential to add or delete firing patterns from the brain’s native cells. Additionally, brain cell firing can be manipulated at precise millisecond intervals. The fiber-optic light source can be mounted on the skull, or placed deep within the brain. The genetics part of optogenetics utilizes simple virus carrier systems to deliver genes to the brain. The most important of these genetic deliveries has been opsin. Opsin is one of the structures potentially turned on by the light. The most important known opsin used for this technology is Channelrhodopsin-2, and it was derived by scientists from algae-based systems. By shining light onto the inserted genetic alteration (opsin), scientists can probe the brain’s inner conversations (firing of cells). The technique has allowed investigators to move past the classical genetic manipulation, which has much less specificity.
Last week Kravitz and colleagues (from the pioneering optogenetics group at Stanford) published an important paper in Nature. They were able to demonstrate that optogenetics could either worsen or alternatively improve an animal model of Parkinsonism. The investigators performed a simple experiment where they manipulated the well-established basal ganglia direct and indirect pathways, which are the best known suspects implicated in the genesis of Parkinson’s disease. The authors reported “optogenetic control of direct- and indirect-pathway medium spiny projection neurons (MSNs), achieved through a viral expression of channelrhodopsin-2 in mice with regulatory elements for the dopamine D1 or D2 receptor. Excitation of the indirect-pathway MSNs elicited a parkinsonian state, distinguished by increased freezing, bradykinesia and decreased locomotor initiations. Activation of direct-pathway MSNs reduced freezing and increased locomotion (Kravitz, 2010).” A month prior to this Nature paper, Bass and colleagues from Wake Forest, described an optogenetic approach to controlling dopamine release (Bass, 2010).
Activating brain circuits by using both light and genetics has thus evolved from a science fiction dream into a true reality. The technique will likely be refined over the next decade and it will have tremendous potential to unlock important clues underlying the disease processes ultimately responsible for Parkinson’s disease. Optogenetics may also open up novel therapeutic possibilities. We can thus conclude there is a bright future ahead for optogenetics, and there is much hope that this technology will help us shine a light on this common, and often disabling human neurodegenerative condition.
We refer the reader to both of these excellent references which describe optogenetics and also detail recent advances in the Parkinson’s disease research arena.
Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, Kreitzer AC.
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010 Jul 29;466(7306):622-6.
Bass CE, Grinevich VP, Vance ZB, Sullivan RP, Bonin KD, Budygin EA. Optogenetic control of striatal dopamine release in rats.
J Neurochem. 2010 Jun 8.
Posted: 8/3/2010 6:12:27 AM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease